Gemmus Pharma Inc., a San Francisco, CA-based biotechnology company developing an improved host-targeted treatment for influenza, has closed on a Series A funding.
The amount was not disclosed.
The round was led by the Life Science Angels (LSA), with participation from BlueTree Allied Angels, Tech Coast Angels, Wilmington Investor Network and The Angels Forum.
The company intends to use the funding to to prepare for an IND filing of a candidate therapy that reduces symptoms during influenza infections by modulating the body’s own beneficial immune response.
Founded in 2007 and led by Daryl Faulds, PhD, CEO, and William Guilford PhD, President, Gemmus develops EP2 and EP4 agonists for the treatment of influenza and in-licensed technology from a major pharmaceutical company. It is a member of the QB3 network, a San Francisco Bay Area Biotech incubator associated with UCSF Mission Bay campus.